- Home
- LBTYK vs VKTX Comparison
LBTYK vs VKTX Comparison
Compare LBTYK & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | VKTX |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LBTYK | VKTX |
|---|---|---|
| Price | $10.93 | $38.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $95.86 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 02-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $22.96 |
| 52 Week High | $13.12 | $43.15 |
Technical Indicators
Market Signals| Indicator | LBTYK | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 73.64 |
| Support Level | $10.52 | $33.65 |
| Resistance Level | $11.51 | $39.78 |
| Average True Range (ATR) | 0.34 | 1.92 |
| MACD | -0.07 | 1.07 |
| Stochastic Oscillator | 22.15 | 87.55 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.